Shaker Investments LLC OH continued to hold its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,000 shares of the company’s stock at the end of the second quarter. Shaker Investments LLC OH’s holdings in IDEXX Laboratories were worth $323,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. 1st Global Advisors Inc. raised its stake in shares of IDEXX Laboratories by 1.2% in the first quarter. 1st Global Advisors Inc. now owns 7,548 shares of the company’s stock valued at $1,167,000 after buying an additional 88 shares during the period. Sei Investments Co. raised its stake in shares of IDEXX Laboratories by 76.6% in the first quarter. Sei Investments Co. now owns 20,277 shares of the company’s stock valued at $3,135,000 after buying an additional 8,792 shares during the period. AXA raised its stake in shares of IDEXX Laboratories by 52.0% in the first quarter. AXA now owns 346,593 shares of the company’s stock valued at $53,587,000 after buying an additional 118,643 shares during the period. Cutler Group LP raised its stake in shares of IDEXX Laboratories by 65.2% in the second quarter. Cutler Group LP now owns 3,800 shares of the company’s stock valued at $613,000 after buying an additional 1,500 shares during the period. Finally, Stephens Investment Management Group LLC raised its stake in shares of IDEXX Laboratories by 0.3% in the first quarter. Stephens Investment Management Group LLC now owns 282,580 shares of the company’s stock valued at $43,690,000 after buying an additional 751 shares during the period. 89.80% of the stock is owned by hedge funds and other institutional investors.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at 155.49 on Tuesday. The company has a market cap of $13.57 billion, a price-to-earnings ratio of 53.49 and a beta of 0.49. IDEXX Laboratories, Inc. has a 52 week low of $102.45 and a 52 week high of $173.01. The firm’s 50-day moving average price is $163.95 and its 200 day moving average price is $154.43.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The business had revenue of $508.90 million during the quarter, compared to the consensus estimate of $502.44 million. During the same quarter in the prior year, the firm earned $0.74 EPS. The business’s revenue was up 9.1% on a year-over-year basis. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post $3.17 EPS for the current year.

IDEXX Laboratories declared that its Board of Directors has approved a share buyback plan on Wednesday, May 3rd that allows the company to repurchase 3,000,000 shares. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

WARNING: This news story was first reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/08/idexx-laboratories-inc-nasdaqidxx-position-held-by-shaker-investments-llc-oh.html.

IDXX has been the subject of several research analyst reports. BidaskClub lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $181.00 price target for the company in a research note on Tuesday, April 25th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price target (up previously from $165.00) on shares of IDEXX Laboratories in a research note on Friday, April 28th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research note on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Hold” and an average target price of $173.80.

In other IDEXX Laboratories news, insider Giovani Twigge sold 2,572 shares of the stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $166.90, for a total transaction of $429,266.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Jonathan W. Ayers sold 27,000 shares of the stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $162.69, for a total transaction of $4,392,630.00. Following the transaction, the chairman now directly owns 1,024,994 shares of the company’s stock, valued at approximately $166,756,273.86. The disclosure for this sale can be found here. Insiders have sold a total of 47,572 shares of company stock valued at $7,816,307 in the last three months. Insiders own 2.77% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.